NEPA is a new oral fixed-dose combination of @ mg netupitant , a highly selective NK@ receptor antagonist ( RA ) and @ mg palonosetron ( PALO ) , a pharmacologically and clinically distinct @-HT@ RA , which targets dual antiemetic pathways .